Kolkata News Today

Bladder Cancer Therapeutics Pipeline Assessment | Insights into the Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, Treatment Outlook, and Key Companies

 Breaking News
  • No posts were found

Bladder Cancer Therapeutics Pipeline Assessment | Insights into the Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, Treatment Outlook, and Key Companies

August 16
17:40 2022
Bladder Cancer Therapeutics Pipeline Assessment | Insights into the Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, Treatment Outlook, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, nearly 100+ key pharma and biotech companies are working on 100+ pipeline drugs in the Bladder Cancer therapeutics landscape based on different routes of administration (RoA), Mechanism of Action (MoA) and molecule types. Several of the therapies are in the advanced stages of clinical development expected to launch in the coming years.

Bladder Cancer Pipeline Insight, 2022” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bladder Cancer Market. 

The Bladder Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

DelveInsight’s “Bladder Cancer Pipeline Insight” Report covers around 100+ products under different phases of clinical development like – 

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

 Bladder Cancer Pipeline Analysis

Bladder Cancer Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Bladder Cancer with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Bladder Cancer Treatment.

  • Bladder Cancer key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Bladder Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Bladder Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight

Bladder Cancer Therapeutics Landscape

There are approx. 100+ key companies which are developing therapies for Bladder cancer. Currently, CG Oncology has its Bladder cancer drug candidates in the most advanced stage of clinical development. 

Some of the key companies in the Bladder Cancer Market include:

CG Oncology, ImmunityBio, UroGen, G1 Therapeutics, FKD Therapies, Bristol-Myers Squibb, LintonPharm, Nektar Therapeutics, Hamlet Pharma AB, Asieris Pharmaceuticals, Wuhan Binhui Biotechnology, Pfizer, Taizhou Hanzhong biomedical co. LTD, Hoffmann-La Roche, Protara Therapeutics, AstraZeneca, CicloMed LLC, enGene, Inc., Emtora Biosciences, Qilu Pharmaceutical Co., Ltd., Theralase Inc., Vaxiion Therapeutics, Janssen Research & Development, LLC, Seagen Inc., RemeGen Co., Ltd., Taiho Oncology, Inc., Xennials Therapeutics, Flame Biosciences, Lindis Biotech, Incyte Corporation, Eli Lilly and Company, Daiichi Sankyo, Nektar Therapeutics, Pieris Pharmaceuticals, Inc., Istari Oncology, BeiGene, Vyriad, Inc., Adlai Nortye Biopharma Co., Ltd., Kyowa Kirin, Inc., Infinity Pharmaceuticals, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., HiberCell, Inc., Ikena Oncology, Fusion Pharmaceuticals Inc., GI Innovation, Inc., SOTIO a.s., Celon Pharma SA, Shanghai PerHum Therapeutics Co., Ltd., 4D Pharma PLC, and several others.

Bladder Cancer Therapies covered in the report include:

• CG0070: CG Oncology

• N-803: ImmunityBio

• UGN-102: UroGen

• Trilaciclib: G1 Therapeutics

And many more

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight

Table of Content (ToC)

1. Report Introduction

2. Executive Summary

3. Bladder Cancer Current Treatment Patterns

4. Bladder Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Bladder Cancer Late Stage Products (Phase-III)

7. Bladder Cancer Mid-Stage Products (Phase-II)

8. Bladder Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Bladder Cancer Discontinued Products

13. Bladder Cancer Product Profiles

14. Key Companies in the Bladder Cancer Market

15. Key Products in the Bladder Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. Bladder Cancer Unmet Needs

18. Bladder Cancer Future Perspectives

19. Bladder Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

 

Other Trending Healthcare Report by DelveInsight

Tongue Cancer Market
“Tongue Cancer Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Tongue Cancer Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the Tongue Cancer therapeutics Market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/